Skip Navigation



Annals of Oncology Advance Access published online on September 8, 2005
Annals of Oncology, doi:10.1093/annonc/mdi325
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
16/10/1709    most recent
mdi325v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Normanno, N.
Right arrow Articles by Menard, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Normanno, N.
Right arrow Articles by Menard, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology

Letter to the Editor

Is the gefitinib plus trastuzumab combination feasible in breast cancer patients?

N. Normanno 1*, M. Campiglio 2, F. Perrone 3, A. De Luca 1, and S. Menard 2

1 Cell Biology and Preclinical Models Unit, INT-Fondazione Pascale, 80131 Naples, Italy
2 Molecular Targeting Unit, Istituto Tumori Milano, 20133 Milan, Italy
3 Clinical Trials Unit, INT-Fondazione Pascale, 80131 Naples, Italy

* To whom correspondence should be addressed.
N. Normanno, E-mail: nicnorm{at}yahoo.com



This article has no Abstract.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Res.Home page
D. L. Shattuck, J. K. Miller, K. L. Carraway III, and C. Sweeney
Met Receptor Contributes to Trastuzumab Resistance of Her2-Overexpressing Breast Cancer Cells
Cancer Res., March 1, 2008; 68(5): 1471 - 1477.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G Valabrega, F Montemurro, and M Aglietta
Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer
Ann. Onc., June 1, 2007; 18(6): 977 - 984.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.